Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report.
- Authors: CORRAO S; PISTONE G; ARNONE S; CALVO L; SCAGLIONE R; LICATA G
- Publication year: 2009
- Type: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/21874
We enrolled nine consecutive patients affected by newly diagnosed polymyalgia rheumatica and decompensated diabetes mellitus. All patients were treated with etanercept (25 mg twice weekly) and prednisone and were followed up to 1 year. At the sixth-month follow-up, etanercept and prednisone were withdrawn. Patients were seen at regular intervals (days 0, 30, 60, 90, 150, 180) and the following variables determined: erythrocytes sedimentation rate, C-reactive protein, fasting serum glucose, pain measured by visual analog scale, and the Health Assessment Questionnaire. Our results indicate that etanercept might have some steroid-sparing effects, but controlled investigations are needed to support etanercept use in clinical practice for this kind of patients.